Focus Stocks
Near Key Levels: GlaxoSmithKline
Published on Monday, 10 September 2012 08:56 Written by TradersHuddle Wire
New York, September 10th (TradersHuddle.com) - GlaxoSmithKline plc (NYSE:GSK) closed the the trading session at $45.14, near its 50 day and 200 day moving averages currently set at $45.95 and $45.26 respectively. GlaxoSmithKline's price action places the stock below these important levels, which makes it difficult to be bought, as it will certainly face resistance as it approaches these important moving averages.
GlaxoSmithKline plc (NYSE:GSK) is a research-based pharmaceutical group that develops, manufactures and markets vaccines, prescription and over-the-counter medicines, as well as health-related consumer products. Its over the counter medicines and health related consumer products are marketed under brand names like Panadol, Nicorette, Breathe Right, Tums, Aquafresh, and Sensodyne among others.
The latest price action range, defined by a peaks and troughs algorithm, placed calculated support at $43.77 and resistance at $47.40. Traders should monitor these levels, as they provide insight into the latest price dynamics in GlaxoSmithKline.
If traders want to establish a position on GlaxoSmithKline, given the heavy resistance expected near the 50 and 200 day moving averages, a trade might be evident as the stock manages to break these moving averages. However, until the break materializes buying the stock is nothing different than flipping a coin.
Related Articles
- GlaxoSmithKline Is Near a Key Resistance Area
- BREO™ ELLIPTA™ gains US approval for the treatment of COPD
- Trading Idea: - Is GlaxoSmithKline close to Resistance?
- GlaxoSmithKline Is Moving Above Resistance
- GlaxoSmithKline Is Near a Key Resistance Area
- GlaxoSmithKline Is Moving Above Resistance
- GlaxoSmithKline CFO Interviewed on Q1 2013 Financial Results
- GlaxoSmithKline Is Near a Key Resistance Area
- Above Resistance: GlaxoSmithKline
- FDA Advisory Committee recommends approval of BREO™ ELLIPTA™ for the treatment of COPD
Related Partner Headlines
- GlaxoSmithKline Stock To Go Ex-dividend Tomorrow (GSK) - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Drugs Laggard - TheStreet.com
- Buzz on Sarepta's Eteplirsen From London Duchenne Meeting - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Health Care Winner - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Health Care Winner - TheStreet.com
- United Therapeutics Could Lose The Battle For PAH Therapies - TheStreet.com
- A Prescription for Election Fever - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Drugs Laggard - TheStreet.com
- How to Hedge Profits in Sarepta Therapeutics - TheStreet.com
- Lazard Analyst Note on Sarepta Therapeutics Is Generating Buzz - TheStreet.com
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Technical Scans
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,294.50 Trade time:4:53PM EDT Value change:▼12.67 (-0.08%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,650.51 Trade time:4:52PM EDT Value change:▼4.84 (-0.29%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,459.42 Trade time:5:15PM EDT Value change:▼3.88 (-0.11%)In The Wires
-
Crest Supplements its Proxy Statement Opposing Revised Terms for Sprint-Clearwire Merger -
Novelis and CEO Philip Martens Win Top Honors at Platts Global Metals Awards -
Venaxis Announces Pricing of Offering of Common Stock and Warrants -
Synopsys Delivers VDK for Renesas RH850 MCUs -
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitamin Shoppe, Inc. - VSI -
Ecologic Transportation, Inc. Announces A Corporate Update Conference Call -
Northrop Grumman Increases Investment in Australia, Expands Industry Partnerships -
Novelis Wins "CEO" and "Company of the Year" Titles at Platts Global Metals Awards








